Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $46.43 Consensus Price Target from Analysts

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $46.43.

Several research analysts recently weighed in on OTLK shares. Brookline Capital Management raised shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $31.40 target price for the company in a report on Thursday, January 25th. Ascendiant Capital Markets increased their price objective on shares of Outlook Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 29th. Capital One Financial reaffirmed an “overweight” rating on shares of Outlook Therapeutics in a research report on Friday, February 16th. Guggenheim upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Thursday, January 25th. Finally, Chardan Capital upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $60.00 price objective on the stock in a research note on Thursday, February 15th.

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors have recently bought and sold shares of OTLK. BlackRock Inc. lifted its stake in shares of Outlook Therapeutics by 14.2% during the second quarter. BlackRock Inc. now owns 9,215,800 shares of the company’s stock worth $16,035,000 after buying an additional 1,148,372 shares during the period. State Street Corp lifted its stake in shares of Outlook Therapeutics by 36.2% during the second quarter. State Street Corp now owns 2,751,977 shares of the company’s stock worth $4,788,000 after buying an additional 731,925 shares during the period. Geode Capital Management LLC lifted its stake in shares of Outlook Therapeutics by 23.1% during the first quarter. Geode Capital Management LLC now owns 2,537,675 shares of the company’s stock worth $2,766,000 after buying an additional 475,477 shares during the period. Vanguard Group Inc. lifted its stake in shares of Outlook Therapeutics by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 6,560,400 shares of the company’s stock worth $2,585,000 after buying an additional 277,326 shares during the period. Finally, Scotia Capital Inc. lifted its stake in shares of Outlook Therapeutics by 420.9% during the third quarter. Scotia Capital Inc. now owns 338,439 shares of the company’s stock worth $75,000 after buying an additional 273,463 shares during the period. 11.20% of the stock is currently owned by institutional investors and hedge funds.

Outlook Therapeutics Stock Down 0.9 %

Shares of OTLK opened at $8.62 on Friday. Outlook Therapeutics has a 52 week low of $4.00 and a 52 week high of $40.60. The stock has a market cap of $112.17 million, a P/E ratio of -2.16 and a beta of 0.04. The business’s 50 day moving average price is $8.57 and its 200-day moving average price is $8.32.

Outlook Therapeutics (NASDAQ:OTLK) last announced its earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.20. On average, equities analysts anticipate that Outlook Therapeutics will post -2.99 EPS for the current year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.